NEW YORK, Sept. 12, 2016 /PRNewswire/ -- Delcath
Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company
focused on the treatment of primary and metastatic liver cancers,
announces that Company management will participate at the 2016
Aegis Growth Conference taking place from September 20-22, 2016 in Las Vegas. Jennifer K.
Simpson, Ph.D., MSN, CRNP, President and Chief Executive
Officer of Delcath, will present a corporate overview on
September 21st at 2:00 p.m. Pacific time.
Dr. Simpson's presentation at the 2016 Aegis Growth Conference
will be webcast live and will be archived on the Company's website
at www.delcath.com.
About Delcath Systems
Delcath Systems, Inc. is an interventional oncology Company
focused on the treatment of primary and metastatic liver cancers.
Our investigational product—Melphalan Hydrochloride for Injection
for use with the Delcath Hepatic Delivery System (Melphalan/HDS)
—is designed to administer high-dose chemotherapy to the liver
while controlling systemic exposure and associated side effects. We
have commenced a global Phase 3 FOCUS clinical trial for Patients
with Hepatic Dominant Ocular Melanoma (OM) and a global Phase 2
clinical trial in Europe and the U.S. to investigate the
Melphalan/HDS system for the treatment of primary liver cancer
(HCC) and intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has
not been approved by the U.S. Food & Drug Administration (FDA)
for sale in the U.S. In Europe, our system has been
commercially available since 2012 under the trade name Delcath
Hepatic CHEMOSAT® Delivery System for Melphalan
(CHEMOSAT), where it has been used at major medical centers to
treat a wide range of cancers of the liver.
Investor Contact:
Anne Marie
Fields
LHA
212-838-3777
afields@lhai.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/delcath-to-present-at-the-2016-aegis-growth-conference-300326360.html
SOURCE Delcath Systems, Inc.